AbbVie
Genmab to submit FDA application for lymphoma therapy
May 2, 2025Research and Development AbbVie, Biologics License Application, FDA, Genmab, Oncology, epcoritamab, lymphoma, therapeutics
Global biotechnology company Genmab plans to submit a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) …
The National Institute for Health and Care Excellence announce technology appraisal guidance recommending risankizumab for adult patients with moderate to severe ulcerative colitis
August 29, 2024Research and Development AbbVie, Crohns, Gastrointestinal tract, Immunology, NICE, approval, ulcerative colitis
The National Institute for Health and Care Excellence (NICE) have recommended adult patients in England or Wales with moderately or …
Abbvie acquires Cerevel Therapeutics
August 2, 2024Mergers and Acquisitions AbbVie, Cerevel Therapeutics, Drug-Resistant Epilepsy, Neurology, Parkinson's disease, major depressive disorder, mergers & acquisitions, neurology, neuroscience, schizophrenia
Abbvie has announced the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline. Cerevel has multiple programmes across neurological and psychiatric …
AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment
June 28, 2024Medical Communications AbbVie, CHMP, EMA, Oncology, follicular lymphoma
AbbVie has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a …
FDA approves AbbVie’s Skyrizi for UC treatment
June 20, 2024Medical Communications AbbVie, FDA, Gastrointestinal tract, UC, ibd
AbbVie has announced that the US Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa) for the treatment of adult …
AbbVie initiates phase 3 multiple myeloma trial
June 6, 2024Medical Communications ABBV-383, AbbVie, Oncology, clinical trial, multiple myeloma
AbbVie has announced that it has dosed the first patient in its phase 3 CERVINO trial, which aims to assess …
AbbVie gains positive CHMP opinion for Skyrizi for treatment of UC
May 31, 2024Medical Communications AbbVie, EMA, Gastrointestinal tract, Skyrizi, ulcerative colitis
AbbVie has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a …
AbbVie invests €150m in new R&D facility in Germany
May 3, 2024Research and Development AbbVie, Pharmacy, R&D, facility
AbbVie has announced that it is investing approximately €150m in its second largest research and development (R&D) facility worldwide. The …
Medincell and AbbVie enter agreement for development of next-generation injectables
April 17, 2024Research and Development AbbVie, Immunology, Medincell, collaboration
Medincell and AbbVie have announced that they have entered into a collaboration to co-develop and commercialise up to six next-generation …
AbbVie to acquire Landos Biopharma for approximately $137.5m
March 26, 2024Business Services AbbVie, Landos Biopharma, Pharmacy, acquisition
AbbVie and Landos Biopharma have announced that they have entered into a definitive agreement under which AbbVie will acquire Landos …
AbbVie and Tentarix collaborate on oncology and immunology treatments
February 23, 2024Research and Development AbbVie, Oncology, collaboration, immunology
AbbVie and Tentarix Biotherapeutics have announced that they have entered a multi-year collaboration focused on the discovery and development of …
NICE recommends SC treatment of AbbVie’s Tepkinly for patients with DLBCL
February 1, 2024Medical Communications AbbVie, DLBCL, NICE, Oncology, lymphoma
AbbVie has announced that the National Institute for Health and Care Excellence (NICE) has recommended Tepkinly (epcoritamab) as a treatment …
AbbVie invests $223m in Singapore manufacturing site
January 26, 2024Manufacturing and Production AbbVie, Pharmacy, Singapore, manufacturing
AbbVie has announced that it has invested $223m in an expansion to its Singapore manufacturing facility. This will create more …
AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn
December 7, 2023Business Services AbbVie, Cerevel Therapeutics, Neurology, acquisition
AbbVie and Cerevel Therapeutics have announced an agreement in which AbbVie will acquire Cerevel Therapeutics for $45 per share, or …
AbbVie to acquire ImmunoGen for approximately $10.1bn
December 1, 2023Sales and Marketing AbbVie, Oncology, acquisition
AbbVie and ImmunoGen have announced that AbbVie will acquire ImmunoGen and its lead cancer therapy Elahere (mirvetuximab soratansine-gynx), a first …
Latest content
FibroFind appoints Lee Borthwick as CEO
